All In Biotech

Drug Trial Radar · NCT04886765

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

A Phase I/II, Multi-center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Last checked: Nov 20, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

238

Planned (sponsor's estimate)

Start

May 2021

Primary completion

Nov 2023

Study completion May 2024

Sponsor

Sponsor type
Industry
Collaborators
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
First posted
May 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I / II, multi-center, single-arm, open-label study to evaluate the safety and efficacy of ALMB-0168 in patients with osteosarcoma whose prior standard treatment have failed.

Conditions

  • Osteosarcoma

Interventions

  • ALMB-0168Drug

    ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: From enrollment to 28 days after the last dose in each part study.
  2. Dose-Limited Toxicities (DLT)Time frame: Up to 21 days in Cycle 1
  3. 6-Month Progression-free Survival Rate (6m-PFSR)Time frame: From enrollment to 6 month after the first dose of the last patient in PART II

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.